+关注
楚楚要发财
暂无个人介绍
IP属地：浙江
3
关注
0
粉丝
3
主题
0
勋章
主贴
热门
楚楚要发财
2025-12-30
太垃圾了
异动解读 | 翰思艾泰-B盘中大跌13.11%，上市后持续承压，临床管线风险引担忧
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4203676840742872","uuid":"4203676840742872","gmtCreate":1740573663912,"gmtModify":1740624541994,"name":"楚楚要发财","pinyin":"ccyfcchuchuyaofacai","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":3,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.17","exceedPercentage":"80.98%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.24","exceedPercentage":"60.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"浙江","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":2,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":516185108550744,"gmtCreate":1767042411320,"gmtModify":1767044233558,"author":{"id":"4203676840742872","authorId":"4203676840742872","name":"楚楚要发财","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4203676840742872","idStr":"4203676840742872"},"themes":[],"title":"","htmlText":"太垃圾了","listText":"太垃圾了","text":"太垃圾了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/516185108550744","repostId":"1136212543","repostType":2,"repost":{"id":"1136212543","kind":"news","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"异动解读","id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1766977346,"share":"https://www.laohu8.com/m/news/1136212543?lang=zh_CN&edition=full","pubTime":"2025-12-29 11:02","market":"nz","language":"zh","title":"异动解读 | 翰思艾泰-B盘中大跌13.11%，上市后持续承压，临床管线风险引担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1136212543","media":"异动解读","summary":"翰思艾泰-B今日盘中大跌13.11%，延续了其上市以来的疲软表现。消息面上，翰思艾泰-B自12月23日登陆港股以来表现不佳，上市首日即暴跌46.25%，市值缩水至约20亿元人民币。翰思艾泰-B的研发投入有限，却选择了CD47这一高难度靶点，而全球尚无同类药物成功获批。叠加公司短期内难以商业化的预期，市场对其长期价值持谨慎态度，导致股价持续承压。","content":"<p>翰思艾泰-B（03378）今日盘中大跌13.11%，延续了其上市以来的疲软表现。</p><p>消息面上，翰思艾泰-B自12月23日登陆港股以来表现不佳，上市首日即暴跌46.25%，市值缩水至约20亿元人民币。公司核心产品HX009（靶向PD-L1与CD47的双功能融合蛋白）仍处于早期临床阶段，面临极高的研发失败风险。此外，公司背负对赌协议，若核心管线未能在2026年底前提交上市申请，投资者有权要求赎回股份，进一步加剧了市场对其资金压力的担忧。</p><p>翰思艾泰-B的研发投入有限（2025年前8个月仅5617万元），却选择了CD47这一高难度靶点，而全球尚无同类药物成功获批。叠加公司短期内难以商业化的预期，市场对其长期价值持谨慎态度，导致股价持续承压。</p>","source":"ai_movement_cn","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 翰思艾泰-B盘中大跌13.11%，上市后持续承压，临床管线风险引担忧</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 翰思艾泰-B盘中大跌13.11%，上市后持续承压，临床管线风险引担忧\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-12-29 11:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>翰思艾泰-B（03378）今日盘中大跌13.11%，延续了其上市以来的疲软表现。</p><p>消息面上，翰思艾泰-B自12月23日登陆港股以来表现不佳，上市首日即暴跌46.25%，市值缩水至约20亿元人民币。公司核心产品HX009（靶向PD-L1与CD47的双功能融合蛋白）仍处于早期临床阶段，面临极高的研发失败风险。此外，公司背负对赌协议，若核心管线未能在2026年底前提交上市申请，投资者有权要求赎回股份，进一步加剧了市场对其资金压力的担忧。</p><p>翰思艾泰-B的研发投入有限（2025年前8个月仅5617万元），却选择了CD47这一高难度靶点，而全球尚无同类药物成功获批。叠加公司短期内难以商业化的预期，市场对其长期价值持谨慎态度，导致股价持续承压。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03378":"翰思艾泰-B"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136212543","content_text":"翰思艾泰-B（03378）今日盘中大跌13.11%，延续了其上市以来的疲软表现。消息面上，翰思艾泰-B自12月23日登陆港股以来表现不佳，上市首日即暴跌46.25%，市值缩水至约20亿元人民币。公司核心产品HX009（靶向PD-L1与CD47的双功能融合蛋白）仍处于早期临床阶段，面临极高的研发失败风险。此外，公司背负对赌协议，若核心管线未能在2026年底前提交上市申请，投资者有权要求赎回股份，进一步加剧了市场对其资金压力的担忧。翰思艾泰-B的研发投入有限（2025年前8个月仅5617万元），却选择了CD47这一高难度靶点，而全球尚无同类药物成功获批。叠加公司短期内难以商业化的预期，市场对其长期价值持谨慎态度，导致股价持续承压。","news_type":1,"symbols_score_info":{"03378":1}},"isVote":1,"tweetType":1,"viewCount":363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":516185108550744,"gmtCreate":1767042411320,"gmtModify":1767044233558,"author":{"id":"4203676840742872","authorId":"4203676840742872","name":"楚楚要发财","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203676840742872","authorIdStr":"4203676840742872"},"themes":[],"title":"","htmlText":"太垃圾了","listText":"太垃圾了","text":"太垃圾了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/516185108550744","repostId":"1136212543","repostType":2,"repost":{"id":"1136212543","kind":"news","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"异动解读","id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1766977346,"share":"https://www.laohu8.com/m/news/1136212543?lang=zh_CN&edition=full","pubTime":"2025-12-29 11:02","market":"nz","language":"zh","title":"异动解读 | 翰思艾泰-B盘中大跌13.11%，上市后持续承压，临床管线风险引担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1136212543","media":"异动解读","summary":"翰思艾泰-B今日盘中大跌13.11%，延续了其上市以来的疲软表现。消息面上，翰思艾泰-B自12月23日登陆港股以来表现不佳，上市首日即暴跌46.25%，市值缩水至约20亿元人民币。翰思艾泰-B的研发投入有限，却选择了CD47这一高难度靶点，而全球尚无同类药物成功获批。叠加公司短期内难以商业化的预期，市场对其长期价值持谨慎态度，导致股价持续承压。","content":"<p>翰思艾泰-B（03378）今日盘中大跌13.11%，延续了其上市以来的疲软表现。</p><p>消息面上，翰思艾泰-B自12月23日登陆港股以来表现不佳，上市首日即暴跌46.25%，市值缩水至约20亿元人民币。公司核心产品HX009（靶向PD-L1与CD47的双功能融合蛋白）仍处于早期临床阶段，面临极高的研发失败风险。此外，公司背负对赌协议，若核心管线未能在2026年底前提交上市申请，投资者有权要求赎回股份，进一步加剧了市场对其资金压力的担忧。</p><p>翰思艾泰-B的研发投入有限（2025年前8个月仅5617万元），却选择了CD47这一高难度靶点，而全球尚无同类药物成功获批。叠加公司短期内难以商业化的预期，市场对其长期价值持谨慎态度，导致股价持续承压。</p>","source":"ai_movement_cn","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 翰思艾泰-B盘中大跌13.11%，上市后持续承压，临床管线风险引担忧</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 翰思艾泰-B盘中大跌13.11%，上市后持续承压，临床管线风险引担忧\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-12-29 11:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>翰思艾泰-B（03378）今日盘中大跌13.11%，延续了其上市以来的疲软表现。</p><p>消息面上，翰思艾泰-B自12月23日登陆港股以来表现不佳，上市首日即暴跌46.25%，市值缩水至约20亿元人民币。公司核心产品HX009（靶向PD-L1与CD47的双功能融合蛋白）仍处于早期临床阶段，面临极高的研发失败风险。此外，公司背负对赌协议，若核心管线未能在2026年底前提交上市申请，投资者有权要求赎回股份，进一步加剧了市场对其资金压力的担忧。</p><p>翰思艾泰-B的研发投入有限（2025年前8个月仅5617万元），却选择了CD47这一高难度靶点，而全球尚无同类药物成功获批。叠加公司短期内难以商业化的预期，市场对其长期价值持谨慎态度，导致股价持续承压。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03378":"翰思艾泰-B"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136212543","content_text":"翰思艾泰-B（03378）今日盘中大跌13.11%，延续了其上市以来的疲软表现。消息面上，翰思艾泰-B自12月23日登陆港股以来表现不佳，上市首日即暴跌46.25%，市值缩水至约20亿元人民币。公司核心产品HX009（靶向PD-L1与CD47的双功能融合蛋白）仍处于早期临床阶段，面临极高的研发失败风险。此外，公司背负对赌协议，若核心管线未能在2026年底前提交上市申请，投资者有权要求赎回股份，进一步加剧了市场对其资金压力的担忧。翰思艾泰-B的研发投入有限（2025年前8个月仅5617万元），却选择了CD47这一高难度靶点，而全球尚无同类药物成功获批。叠加公司短期内难以商业化的预期，市场对其长期价值持谨慎态度，导致股价持续承压。","news_type":1,"symbols_score_info":{"03378":1}},"isVote":1,"tweetType":1,"viewCount":363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
